The Tomosynthesis Mammographic Imaging Screening Trial (TMIST or study EA1151) is a randomized breast cancer screening study. The ECOG-ACRIN Cancer Research Group opened the trial on July 6, 2017, and is currently enrolling about 165,000 women who are planning to have regular mammograms.
TMIST is very important to the future of breast cancer screening because it will give us knowledge about how to move beyond our current “one size fits all” approach, where we screen most women the same way based on age-specific guidelines. The trial will help us move towards a more personalized approach that tailors mammography for each woman based on her own genetics and individual risk factors for developing breast cancer.
Visit the Press Center
Q2 2021 (posted July 16, 2021)
Q1 2021 (posted April 16, 2021)
Q4 2020 (posted January 29, 2021)
Q3 2020 (posted October 21, 2020)
Q2 2020 (posted July 23, 2020)
Q1 2020 (posted April 20, 2020)
Q4 2019 (posted January 15, 2020)
Q3 2019 (posted October 15, 2019)
Q2 2019 (posted July 2, 2019)
Learn about the American College of Radiology recruitment services by visiting acr.org/tmist.
Women ages 45 to 74 who are planning to get a routine screening mammogram are eligible for this trial.
Women who decide to participate in this trial will be involved through the end of the study. Once enrolled in the trial, women will be randomized (assigned by a computer) to get either 3-D or 2-D screening mammograms for five years. Each woman will need to agree to let her doctor tell her how often to get screened—either every year or every other year—based on her individual risks for developing breast cancer.
During the study, the results of every mammogram from every woman will be collected. Information about any medical follow-up, such as more imaging or a biopsy, will also be recorded. All women will be followed until the end of the study for breast cancer status, treatment, and results from treatment.
TMIST is publicly funded by the National Cancer Institute (NCI), part of the National Institutes of Health, through the NCI Community Oncology Research Program.